Day: December 20, 2024

Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo, all administered once-weekly. The trial included 3,417 randomised people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg. The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss at week 68 with CagriSema versus placebo. The REDEFINE 1 trial was based on a flexible protocol, allowing patients to modify their dosing throughout the trial....

Correction: The shares were bought by MMH Nysteen Invest AS, a company controlled by board member Maria Moræus Hanssen and related parties.Oslo, 20 December 2024: MMH Nysteen Invest AS, a company controlled by board member Maria Moræus Hanssen and related parties has on 20 December bought 2,575 shares in Scatec ASA at an average price per share of NOK 77.1. After the transaction MMH Nysteen Invest AS owns 13,615 shares in Scatec ASA.Attached is the notification of the transaction in accordance with the Market Abuse Regulation Article 19. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading act.Attachment241220 – Notification of trade primary insiders – MMH Nysteen Invest AS

SHENZHEN, China, Dec. 20, 2024 (GLOBE NEWSWIRE) — NIP Group Inc. (NASDAQ: NIPG) (“NIP Group” or the “Company”), a leading digital entertainment company, is breaking new ground with the introduction of its first MOBA game: Re: Aetatis. This highly anticipated cutting-edge sci-fi MOBA mobile game begins open beta testing on December 24, 2024, inviting players to experience the next evolution in competitive gaming. Re: Aetatis marks NIP Group’s bold entry into the dynamic game publishing market and a major milestone for the Company’s evolution from a top esports organization to a global digital entertainment leader. Following the launch of reservations, Re: Aetatis has garnered significant attention and recognition from players and is poised to become a flagship title in NIP Group’s emerging game portfolio. NIP Group is...

Vaisala CorporationManagers’ TransactionsDecember 20, 2024, at 11:30 a.m. (EET) Vaisala Corporation: Managers’ Transactions – Rosenberg, Lotte ____________________________________________ Person subject to the notification requirementName: Rosenberg, LottePosition: Member of the Board/Deputy memberIssuer: Vaisala OyjLEI: 743700RNDD7KU11HW873 Notification type: INITIAL NOTIFICATIONReference number: 88612/6/6____________________________________________ Transaction date: 2024-12-19Venue: TQEAInstrument type: SHAREISIN: FI0009900682Nature of the transaction: DISPOSAL Transaction details(1): Volume: 4 Unit price: 46.65 EUR (2): Volume: 8 Unit price: 46.65 EUR (3): Volume: 23 Unit price: 46.5 EUR (4): Volume: 51 Unit price: 46.65 EUR (5): Volume: 51 Unit price: 46.65 EUR (6): Volume: 49 Unit price: 46.7 EUR (7): Volume: 214 Unit price: 46.65...

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 19740 DKT 03/03/25 I 380 – –   – –98 19823 DKT 02/06/25 II 300 – –   – –Total 680 –      The sale will settle January 2nd 2025.

Tokyo, Japan and Cambridge, UK, 20 December 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that Chris Cargill, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, 15 January 2025 at 3:00 p.m. PST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. Presentation slides will be made available through the investor section of the Company’s website. –END– About Nxera PharmaNxera Pharma (formerly Sosei Heptares) is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan,...

For immediate release 20 December 2024 EIB submits SEC Form 18-K/A Amendment No. 9 The European Investment Bank (EIB) has submitted its SEC Form 18-K/A Amendment No. 9. To view the document, please go to: EDGAR Filing Documents for 0000950157-24-001686 The 18-K/A has also been posted on the EIB website: Amendment to the Annual Report 2023 (Form 18-K/A Amendment No 9) ENDS

LONDON, Dec. 20, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultrarare genetic diseases, today announced that NHS England has implemented the commissioning of Evkeeza (evinacumab) following the National Institute for Health and Care Excellence (NICE) final guidance in September. The use of Evkeeza in eligible people aged 12 years and older will be routinely commissioned by NHS England in line with the NICE TA and will be available in seven hospital trusts in England. In addition, prior approval forms are in place to enable access for children aged 5 to 11 years, via the NHS England Commissioning Medicines for Children policy.  Dr. Jaimini Cegla, clinical lead of the Lipid and Cardiovascular Risk...